GUD

Knight Therapeut

• Dow Jones·08/06 10:34

  *Knight Therapeutics Raises 2026 View To Rev C$540M-C$560M >GUD.T

• Dow Jones·08/06 10:33

  *Knight Therapeutics 2Q Loss/Shr C$0.03 >GUD.T

• Dow Jones·08/06 10:33

  *Knight Therapeutics 2Q Rev C$144.2M >GUD.T

• Dow Jones·05/08 16:12

  Knight Therapeutics Inc Is Maintained at Buy by Canaccord Genuity

• Dow Jones·05/08 16:12

  Knight Therapeutics Inc Price Target Is Maintained at C$9.50/Share by Canaccord Genuity

• Dow Jones·05/07 10:32

  *Knight Therapeutics Raises 2026 View To Rev C$510M-C$525M >GUD.T

• Dow Jones·05/07 10:31

  *Knight Therapeutics 1Q Rev C$148.4M >GUD.T

• Dow Jones·03/23 12:39

  *Knight Therapeutics Increases Share Repurchase Program to 6.19M Shrs, About 10% of Public Float >GUD.T

• Dow Jones·03/19 11:34

  *Knight Therapeutics Sees 2026 Rev C$490M-C$510M >GUD.T

• Dow Jones·03/19 11:30

  *Knight Therapeutics 4Q EPS C$0.09 >GUD.T

• Dow Jones·03/19 11:30

  *Knight Therapeutics 4Q Rev C$133.1M >GUD.T

• Dow Jones·11/11/2025 17:16

  Correction to Knight Therapeutics 3Q Rev Headline on Nov. 6

• Dow Jones·11/11/2025 16:32

  Profound Medical Regains Distribution Rights for Tulsa-Pro Medical Device System

• Dow Jones·11/06/2025 12:44

  *Knight Therapeutics Raises FY25 View To Rev C$430M-C$440M >GUD.T

• Dow Jones·11/06/2025 12:42

  *Correct: Knight Therapeutics 3Q Rev C$121,548 >GUD.T